Standard Biotools Inc.2024财年第三财季实现净利润-26.94百万美元，同比减少28.29%

市场透视11-08

11月8日，Standard Biotools Inc.（LAB.US）公布财报，公告显示公司2024财年第三财季净利润为-26.94百万美元，同比减少28.29%；其中营业收入为44.97百万美元，同比增加77.26%，每股基本收益为-0.07美元。从资产负债表来看，Standard Biotools Inc.（LAB.US）总负债1.84亿美元，其中短期债务61.04百万美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481138872?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-08 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2481138872","market":"us","top_or_hot":-1,"title":"Standard Biotools Inc.2024财年第三财季实现净利润-26.94百万美元，同比减少28.29%","media":"市场透视","content":"<div>\n<p>11月8日，Standard Biotools Inc.（LAB.US）公布财报，公告显示公司2024财年第三财季净利润为-26.94百万美元，同比减少28.29%；其中营业收入为44.97百万美元，同比增加77.26%，每股基本收益为-0.07美元。从资产负债表来看，Standard Biotools Inc.（LAB.US）总负债1.84亿美元，其中短期债务61.04百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000133abaaa0e4&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Standard Biotools Inc.2024财年第三财季实现净利润-26.94百万美元，同比减少28.29%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStandard Biotools Inc.2024财年第三财季实现净利润-26.94百万美元，同比减少28.29%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000133abaaa0e4&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月8日，Standard Biotools Inc.（LAB.US）公布财报，公告显示公司2024财年第三财季净利润为-26.94百万美元，同比减少28.29%；其中营业收入为44.97百万美元，同比增加77.26%，每股基本收益为-0.07美元。从资产负债表来看，Standard Biotools Inc.（LAB.US）总负债1.84亿美元，其中短期债务61.04百万美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000133abaaa0e4&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LAB","symbol_name":"Standard BioTools Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000133abaaa0e4&s=b","article_id":"2481138872","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108000133abaaa0e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2481138872","pubTimestamp":1730995238,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月8日，Standard Biotools Inc.公布财报，公告显示公司2024财年第三财季净利润为-26.94百万美元，同比减少28.29%；其中营业收入为44.97百万美元，同比增加77.26%，每股基本收益为-0.07美元。从资产负债表来看，Standard Biotools Inc.总负债1.84亿美元，其中短期债务61.04百万美元，资产负债比为3.71，流动比率为3.76。机构评级：截至2024年11月8日，当前有3家机构对Standard Biotools Inc.目标价做出预测，其中目标均价为3.08美元，其中最低目标价为2.50美元，最高目标价为4.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"LAB":"Standard BioTools Inc."},"translate_title":"Standard Biotools Inc. achieved net profit of-US $26.94 million in the third fiscal quarter of fiscal 2024, a year-on-year decrease of 28.29%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LAB":0.9},"content_text":"11月8日，Standard Biotools Inc.（LAB.US）公布财报，公告显示公司2024财年第三财季净利润为-26.94百万美元，同比减少28.29%；其中营业收入为44.97百万美元，同比增加77.26%，每股基本收益为-0.07美元。从资产负债表来看，Standard Biotools Inc.（LAB.US）总负债1.84亿美元，其中短期债务61.04百万美元，资产负债比为3.71，流动比率为3.76。机构评级：截至2024年11月8日，当前有3家机构对Standard Biotools Inc.目标价做出预测，其中目标均价为3.08美元，其中最低目标价为2.50美元，最高目标价为4.00美元。公司简介：思百拓仪器科技有限公司开发、制造和销售技术，帮助生物医学研究人员更快地开发药物。公司的工具使用专有的大规模细胞术和微流体技术提供对健康和疾病的见解，这些技术分别用于蛋白质组学和基因组学。公司的部门包括蛋白质组学和基因组学，并从蛋白质组学部门获得了最大的收入。从地理上看，公司的大部分收入来自美洲。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481138872"}